Proove Biosciences Inc

Irvine, CA, United States

Proove Biosciences Inc

Irvine, CA, United States

Time filter

Source Type

Sharma M.,Interventional Pain Institute | Kantorovich S.,Proove Biosciences Inc. | Lee C.,Proove Biosciences Inc. | Anand N.,Proove Biosciences Inc. | And 5 more authors.
Journal of Psychiatric Research | Year: 2017

Objective Pain levels are a key metric in clinical care. However, the assessment of pain is limited to basic questionnaires and physician interpretation, which yield subjective data. Genetic markers of pain sensitivity, such as single nucleotide polymorphisms in the catechol-O-methyltransferase gene, have been shown to be associated with pain perception and have been used to provide objective information about a patient's pain. The goal of this study was to determine if physician treatment adjustments based on genetic tests of pain perception resulted in improved outcomes for patients. Material and methods A prospective, longitudinal study was conducted with 134 chronic non-cancer pain patients genotyped for pain perception-related catechol-O-methyltransferase haplotypes. Physicians were provided with patients’ results and asked to document 1) their assessment of benefit of the genetic test; 2) treatment changes made based on the genetic test; and 3) patient clinical responses to changes implemented. Results Based on genetic testing results, physicians adjusted treatment plans for 40% of patients. When medication changes were made based on genetic testing results, 72% of patients showed improvement in clinical status. When non-pharmacological actions were performed, 69% of physicians felt their patients’ clinical status improved. Moreover, physicians believed the genetic test results were consistent with patient pain levels in 85% of cases. Conclusions These results demonstrate that providing personalized medicine with genetic information related to pain perception affected physician clinical decision-making for a substantial proportion of patients in this study, and that the availability and utilization of this information was a contributing factor in clinical improvement. © 2017 Elsevier Ltd


Meshkin B.,Proove Biosciences Inc | Lewis K.,Spokane Spine Center | Kantorovich S.,Proove Biosciences Inc | Anand N.,Proove Biosciences Inc | Davila L.,Proove Biosciences Inc
International Journal of Biomedical Science | Year: 2015

Published guidelines for treating injured workers include the need for personalized treatment to manage chronic pain symptoms and increase functional status. However, they often fail to clarify how to objectively personalize these treatments. Further, certain patients need analgesic relief beyond the short term. In these cases, it is not sufficient or reasonable to utilize the typical broad protocol-based justifications for reduction of opioids and other medications in a haphazard manner based purely on poor response, without attempting to elucidate possible pharmacogenetic reasons for this. These guidelines acknowledge the problem of substance abuse and set forth methods for treatment and prevention. Although it has been established in the scientific community that an individual’s experience of pain and likelihood for addiction both have genetic components, genetic testing is not routinely included as part of the overall treatment plan for injured workers with chronic pain. Because decisions in cases of workplace injury should be based on scientific evidence, genetic testing results can add some objective information to the existing subjective and objective clinical data; help ascertain the efficacy and potential for toxicity of treatment; and therefore provide more information for accurate clinical decisions. We propose the addition of genetic testing to consensus guidelines for treating injured workers in order to improve patients’ functional status, increase productivity, improve safety of prescribing, decrease the likelihood of substance abuse, and save on overall healthcare costs. © 2015 Brian Meshkin et al.


Trademark
Proove Biosciences Inc. | Date: 2016-01-05

Genetic tests comprised of DNA detection chemicals or biologicals to medical doctors, genetic scientists and healthcare professionals; Assays or reagents in the nature of DNA detection chemicals or biologicals for use in genetic research to medical doctors, genetic scientists and healthcare professionals. Preparations in the nature of DNA detection chemicals or biologicals for detecting genetic predispositions for health treatment purposes to medical doctors, genetic scientists and healthcare professionals. Consulting services in the fields of laboratory genetic testing or pharmacogenetics to medical doctors, genetic scientists and healthcare professionals; Genetic testing for scientific and medical research purposes to medical doctors, genetic scientists and healthcare professionals; Providing information in the field of pharmacogenetics or genetic research resources to medical doctors, genetic scientists and healthcare professionals; Providing genetic testing services or information in the field of pharmacogenetics or genetic research for scientific research purposes to medical doctors, genetic scientists and healthcare professionals; Research in the field of genetics or pharmacogenetics; Services in the nature of providing genetic testing results for scientific research purposes to medical doctors, genetic scientists and healthcare professionals.


Trademark
Proove Biosciences Inc. | Date: 2015-01-23

preparations for detecting genetic predispositions for health treatment purposes. consulting services in the fields of laboratory testing, diagnostics, pharmacogenetics and genetic research; Genetic testing for research purposes; Providing information in the field of pharmacogenetics and genetic research resources; Providing genetic testing services and information in the field of pharmacogenetics and genetic research; Research in the field of genetics and pharmacogenetics; Services in the nature of providing genetic testing results.


Trademark
Proove Biosciences Inc. | Date: 2014-06-10

preparations for detecting genetic predispositions for health treatment purposes. consulting services in the fields of laboratory testing, diagnostics, pharmacogenetics and genetic research; Genetic testing for research purposes; Providing information in the field of pharmacogenetics and genetic research resources; Providing genetic testing services and information in the field of pharmacogenetics and genetic research; Research in the field of genetics and pharmacogenetics; Services in the nature of providing genetic testing results.


Trademark
Proove Biosciences Inc. | Date: 2014-06-10

preparations for detecting genetic predispositions for health treatment purposes. consulting services in the fields of laboratory testing, diagnostics, pharmacogenetics and genetic research; Genetic testing for research purposes; Providing information in the field of pharmacogenetics and genetic research resources; Providing genetic testing services and information in the field of pharmacogenetics and genetic research; Research in the field of genetics and pharmacogenetics; Services in the nature of providing genetic testing results.


Trademark
Proove Biosciences Inc. | Date: 2014-06-10

preparations for detecting genetic predispositions for health treatment purposes. consulting services in the fields of laboratory testing, diagnostics, pharmacogenetics and genetic research; Genetic testing for research purposes; Providing information in the field of pharmacogenetics and genetic research resources; Providing genetic testing services and information in the field of pharmacogenetics and genetic research; Research in the field of genetics and pharmacogenetics; Services in the nature of providing genetic testing results.


Trademark
Proove Biosciences Inc. | Date: 2013-10-08

Computer software for controlling or managing patient record information; Computer software for the collection, editing, organizing, modifying, transmission, storage or sharing of data and information; Computer software for scientific analysis of genetic sequences or alleles; Laboratory devices for detecting genetic sequences or alleles. Services in the nature of business information processing relating to genetic data. Providing health-related information, consultancy or advisory services for health treatment purposes; Genetic counseling; Genetic tests for health treatment purposes; Providing information, advice or data on genetic testing results for medical purposes; Health treatment services, namely, providing medical prognosis information based on collected and processed genetic data; Medical services in the nature of providing genetic testing and genetic testing results for medical purposes.


Trademark
Proove Biosciences Inc. | Date: 2013-10-08

Genetic tests comprised of DNA detection reagents to medical doctors, genetic scientists and healthcare professionals; Assays or reagents in the nature of DNA detection chemicals and biologicals for use in genetic research to medical doctors, genetic scientists and healthcare professionals. Preparations in the nature of DNA detection chemicals and biologicals for detecting genetic predispositions for health treatment purposes to medical doctors, genetic scientists and healthcare professionals. Consulting services in the fields of laboratory genetic testing or pharmacogenetics to medical doctors, genetic scientists and healthcare professionals; Genetic testing for scientific and medical research purposes to medical doctors, genetic scientists and healthcare professionals; Providing information in the field of pharmacogenetics or genetic research resources to medical doctors, genetic scientists and healthcare professionals; Providing genetic testing services or information in the field of pharmacogenetics or genetic research for scientific research purposes to medical doctors, genetic scientists and healthcare professionals; Research in the field of genetics or pharmacogenetics; Services in the nature of providing genetic testing results for scientific research purposes to medical doctors, genetic scientists and healthcare professionals.


There are systems and methods for preparing or using prognostic information about pain perception or performing an assay based on such information. The information may include whether subject has a subject genotype that includes a COMT haplotype diploid, at least two SNP diploids, one or more demographic phenotypes or a combination thereof. The COMT haplotype diploid is a combination of two COMT haplotypes selected from an LPS haplotype, an APS haplotype, a HPS haplotype or a combination thereof in the COMT gene. The at least two SNP diploids are each a combination of two SNP alleles associated with one SNP location in the DRD1 gene, the COMT gene, the OPRK1 gene, the DRD2 gene, the MTHFR gene, the SLC6A4 gene, the HTR2A gene, the DBH gene, the GABRG2 gene, the OPRM1 gene or the SLC6A3 gene.

Loading Proove Biosciences Inc collaborators
Loading Proove Biosciences Inc collaborators